Sverre Bengtsson

To successfully implement blended care for patients there’s a crucial step we need to take. 🩺 Hear from Sander Ruitenberg, Digital Health Solutions Head at Novartis what it is: For more insights come to #HTF2024: https://lnkd.in/dbTWjxmy

15

In the ”Future Clinical Trials”, VEIL.AI helped Bayer to anonymize the data with such a high quality that one could draw the same conclusions from the anonymized data as from the traditional pseudonymized individual-level research data. In addition, Findata – Sosiaali- ja terveysalan tietolupaviranomainen | Social and Health Data Permit Authority gave the consent to export the anonymous data from their secure IT environment to Bayer’s secure environment in Germany! #dataanonymization #ehds #clinicaltrials #externalcontrolarms #realworlddata

5

🌐News from the consortium 🌐 Mediconsult Oy has released an interesting article about Integrating AI and LLMs into EHR Systems: Key Architectural Insights. As healthcare evolves, integrating AI and large language models (LLMs) into Electronic Health Record (EHR) systems presents new opportunities—and challenges. We've identified several key architectural considerations that organizations should keep in mind for a successful integration: 🖥️ Resource requirements for AI ⚙️ Performance and asynchronous processing 🔐 Enhanced security and privacy 🚀 Service isolation and API-first integration 📖 Read more about our findings and best practices we've developed along the way with the attached article #HealthcareTechnology #AIinHealthcare #EHR #HealthIT #DataPrivacy #LargeLanguageModels

12

𝐍𝐎𝐑𝐝𝐢𝐜 𝐃𝐚𝐭𝐚𝐬𝐞𝐭 𝐟𝐨𝐫 𝐚𝐒𝐓𝐡𝐦𝐀 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 (𝐍𝐎𝐑𝐃𝐒𝐓𝐀𝐑) – 𝐚 𝐍𝐨𝐫𝐝𝐢𝐜 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 Real-world evidence derived from data collected in routine clinical care is increasingly important for decision-makers in payer and regulatory environments. Nordic health data has several characteristics that enable a globally unique research environment and thus can be used to create globally relevant evidence for decision makers. We at Quantify are proud to be part of NORDSTAR – a multinational, three-party research collaboration with the aim to generate real-world evidence on severe asthma and thereby improving the everyday lives of asthma patients. The NORDSTAR research platform encompasses data collected from Nordic countries (Denmark, Sweden, Norway, Finland) for more than 20 years, including >3 million asthma patients. A variety of outcomes relevant to patients, clinicians, and decision-makers have been investigated, including e.g., severe asthma prevalence, management, and clinical trajectories. The NORDSTAR collaboration comprises of academic asthma researchers in the Nordic Severe Asthma Network (NSAN), pharmaceutical industry sponsors, and Nordic data experts at Quantify Research. This research platform illustrates how a multi-party, public-private partnership built around unique Nordic data and can create impactful research to meet the needs of healthcare practitioners and decision makers globally. Want to know more about NORDSTAR? Please get in contact with us and visit the NORDSTAR website: https://lnkd.in/dYfYEHKN #asthma #realworldevidence #researchcollaboration Quantify Research [email protected] www.quantifyresearch.com

21

The new EU HTA regulation demands more from drug developers—regulatory and HTA processes will now run in parallel. This presents a critical challenge: how do you optimize your teams to manage both without compromising efficiency? In our last webinar, Chantal W.M. van Gils and Maxwell Craig discuss why breaking down silos between clinical development, regulatory, and market access teams is vital for success. Watch the full webinar to learn how to stay ahead. https://lnkd.in/d9B74_Zq At SSI Strategy, we partner with you to develop an evidence and value strategy that meets these new requirements head-on. Don’t let resource misalignment slow your path to market. Let's talk! [email protected]

14

The latest issue of Nordic Life Science Magazine features an interesting article by IQVIA's Jennifer Lees. Learn about Diabetes challenges and funding dilemmas from an International and a Nordic perspective. "It is no secret that obesity is one of the biggest public health challenges of the 21st century and is one of the leading causes of preventable death globally. It’s estimated that 18% of the global population is obese, with the prevalence of obesity in the Nordics falling between 15% to 21%, with these numbers only expected to increase..." Read the full article here: https://lnkd.in/dv2ZXsRu

21

Sweden’s Karolinska University Hospital has adopted a new healthcare model centered on the openEHR digital health platform. This open data framework is a departure from traditional electronic medical record systems, aiming to minimize reliance on external vendors and enhance control over application development. Delivered by Tietoevry, the Better digital health platform facilitates a modular architecture for efficient, scalable, and cost-effective healthcare solutions. CEO of Better, Tomaž Gornik, lauds the hospital's choice as a significant endorsement of openEHR, pushing technological boundaries in healthcare innovation. This strategic shift reflects a broader global trend toward open data standards in healthcare. Read the full article here: https://lnkd.in/ejy5F3BC

2

🔍 Are you leveraging patient insights to drive your clinical research? At James Lind Care, we're dedicated to empowering pharmaceutical companies and organisations with comprehensive patient perspectives. Our approach is rooted in meticulous data collection, extensive research, and insightful analysis from thousands of survey completions and patient interviews. 📊Our reports encompass a diverse range of topics, including insights into specific patient segment and patient engagement strategies tailored to meet specific needs. By delving into our reports, you'll discover how patient insights can revolutionise clinical research, fostering a more patient-centric approach. 💡James Lind Care thrive on collaboration, and we're eager to co-create patient insights with companies, organisations and stakeholders invested in patient-centric research. Reach out to us if you're interested in initiating a dialogue on advancing patient-centric initiatives in clinical research. #PatientInsights  #ClinicalTrials #JamesLindCare #PatientRecruitment LINK: https://lnkd.in/dz_fg7eE

6

The IQVIA Pharmaceutical Market Overview reports for Sweden, Norway and Finland in April 2024 show significant monthly market growth and highlight the top 10 health companies and products by sales. The reports also provide information on the split between prescription-bound and non-prescription-bound products, as well as parallel imports. Stay informed on the latest trends and insights in the pharmaceutical industry with IQVIA Nordics. #pharmaceuticalmarket

19

Balancing cost-containment and market growth in Nordic pharma. Our article investigates and reveals implications for and the impact on #marketdynamics. Download our insightful article today and enhance your market approach. https://bit.ly/4gq8omS #MarketPrognosis

5

Lundbeck Reports Breakthrough in Migraine Therapy with Vyepti #Pharma #PharmaceuticalCompanies #ResearchandDevelopment(R&D) #MarketAccessToday #MarketAccess

2

Iceland Joins FINOSE collaboration for Nordic countries >>The FINOSE collaboration is a joint effort among health economic authorities in Nordic countries to conduct assessments of new medicines. >>It was established in 2018 by Finland, Norway, and Sweden to streamline the evaluation process for new medicinal products. >>With the recent addition of Iceland, all Nordic countries are now part of this collaboration, which also includes Denmark through the Danish Medical Council (DMC). >>The Nordic countries are represented by the following organizations: The Directorate for Medical Products (DMP) in Norway, the Tandvårds- och läkemedelsförmånsverket (TLV) in Sweden, the Finnish Medicines Agency (FIMEA), the Danish Medical Council (DMC), and Iceland's Landspitali (the National University Hospital of Iceland). Why does it matter? =>Enhanced Efficiency and Resource Sharing: By collaborating on method assessments for new medicines, the Nordic countries can pool their resources and expertise, reducing duplication of efforts and speeding up the assessment process. This joint approach is more efficient than each country conducting separate assessments. =>Consistent and Transparent Processes: The FINOSE collaboration aims to create a consistent and transparent process for assessing new medicinal products, providing a clearer pathway for companies seeking approval in the Nordic region. This can lead to more predictable outcomes and reduce uncertainties for pharmaceutical companies. =>Accelerated Market Access: Joint assessments can shorten the time it takes for new medicines to reach the market, benefiting patients by providing quicker access to innovative treatments. This is especially crucial for life-saving or life-improving medicines. =>Reduced Costs and Increased Bargaining Power: A joint approach to assessments can reduce costs for health economic authorities and allow for greater bargaining power during pricing and reimbursement negotiations. This can lead to more favorable pricing, which ultimately benefits healthcare systems and patients. =>Collaboration and Knowledge Sharing: The FINOSE collaboration fosters a sense of unity among the Nordic countries, encouraging collaboration and knowledge sharing among health economic authorities. This can lead to better-informed decisions and improved healthcare outcomes across the region. Credit: Tharun kumar We at MKTXS stay on par with the latest health policy regulations and their implications on the pharmaceutical industry and access to medicines. To book an appointment and learn more about MKTXS and our new AI capabilities Contact us at https://mktxs.com/

8

Which innovative medicines will lead the Nordic market expansion? In this article, IQVIA Market Prognosis identifies therapies, including anti-obesity treatments poised for significant impact. Read the article to assess our analysis and to identify new growth opportunities. https://bit.ly/4eSs0ik #MarketPrognosis #PharmaInnovation #ObesityTreatments

10

#DTP A Significant Session on "Case Study – How Novo Nordisk leverage in silico tools like AI/ML and genetics to reach strategic priorities" by Jakob E. Larsen from at our Digi-Tech Pharma & AI 2024 Conference! #Digitechpharma Corvus Global Events Check out the Conference overview here: https://lnkd.in/gRAvf-D4 Should you have any further queries please email to [email protected] #DrugDiscovery #AI #artificialintelligence #ML #digitaltransformation #HealthIT #PharmaAI #digitalinnovation #aihealthcare #PharmaTechnology #Cloudcomputing #Blockchain #BigData #Drugdiscoverydesign #drugdevelopment #deeplearning #machinelearning #technology #innovation #precisionmedicine #genomics #realworldevidence #translationalmedicine

1

What is the role of collaboration in Oncology Clinical Trials in Sweden……Next EUCROF25 Speaker announced…… EUCROF is thrilled to announce that Annika Baan (Sahlgrenska University Hospital) will be presenting “Code of Conduct in Clinical Trials Oncology Sweden - A work of collaboration” at EUCROF25. Annika will deliver an engaging overview of the long tradition of cooperation between the large clinical trial units in oncology in Sweden, through NASTRO (Network Academic Swedish TRials Oncology), describing the evolution of this clinical trial exchange, illustrating the network’s goal of making Sweden attractive for conducting clinical trials in oncology. View the programme for EUCROF25 here: https://lnkd.in/eEYsx8WT Dr. Martine Dehlinger-Kremer, Simon Lee, Martin O'Kane, Sverre Bengtsson, Benedikt Van Nieuwenhove, Alexandre Malouvier, Antonio Torres, Nicole Bohrmann, Cristina Florescu Moraid, Alan Yeomans, Nira Garty #EUCROF #clinicalresearch #clinicaltrials #clinicaloperations #gcp #bigpharma #dct #EUCROF25

22

What's Next for HTA in 2025? Insights from ISPOR Europe The ISPOR Europe conference in Barcelona highlighted key industry challenges, especially surrounding the upcoming changes to the HTA regulation and its impact on Joint Clinical Assessments (JCA) come January 2025. As the countdown begins, questions around readiness and adaptation remain top of mind for many stakeholders in the healthcare sector. Read our highlights here: https://buff.ly/4f00SOM #LumanityPerspectives #JCA #ISPOREurope

4